MX9601033A - Nanosuspensiones para administracion intravenosa. - Google Patents

Nanosuspensiones para administracion intravenosa.

Info

Publication number
MX9601033A
MX9601033A MX9601033A MX9601033A MX9601033A MX 9601033 A MX9601033 A MX 9601033A MX 9601033 A MX9601033 A MX 9601033A MX 9601033 A MX9601033 A MX 9601033A MX 9601033 A MX9601033 A MX 9601033A
Authority
MX
Mexico
Prior art keywords
staurousporine
intravenous administration
benzoyl
nanosuspensions
water
Prior art date
Application number
MX9601033A
Other languages
English (en)
Other versions
MXPA96001033A (es
Inventor
Hans Weder
Peter Van Hoogevest
Original Assignee
Novartis Ag Tambien Denominada
Y O Novartis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag Tambien Denominada, Y O Novartis Inc filed Critical Novartis Ag Tambien Denominada
Publication of MX9601033A publication Critical patent/MX9601033A/es
Publication of MXPA96001033A publication Critical patent/MXPA96001033A/es

Links

Classifications

    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00Administration; Management
    • G06Q10/08Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06KGRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/0723Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Business, Economics & Management (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Economics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Development Economics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • Tourism & Hospitality (AREA)
  • Neurology (AREA)
  • General Business, Economics & Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)

Abstract

La presente invencion se refiere a una composicion farmacéutica para la administracion intravenosa del derivado de estaurosporina escasamente soluble N-benzoil-estaurosporina. La composicion comprende los siguientes componentes preferidos. a) el agente terapéutico N-benzoil-estaurosporina; b) un copolímero de bloque de polioxietileno/polioxipropileno; c) etanol y agua como líquidos portadores; y d) lecitina purificada de frijol de soya y e) como excipientes solubles en agua, glicerol y sorbitol.
MXPA/A/1996/001033A 1995-03-21 1996-03-19 Nanosuspensiones para administracion intravenosa MXPA96001033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH80495 1995-03-21
CH00804/95 1995-03-21
CH804/95 1995-03-21

Publications (2)

Publication Number Publication Date
MX9601033A true MX9601033A (es) 1997-09-30
MXPA96001033A MXPA96001033A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
IL117550A0 (en) 1996-07-23
KR960034028A (ko) 1996-10-22
HUP9600700A3 (en) 2000-06-28
HUP9600700A2 (en) 1997-02-28
JPH08268893A (ja) 1996-10-15
HU9600700D0 (en) 1996-05-28
NO961137L (no) 1996-09-23
EP0733372A2 (de) 1996-09-25
ZA962248B (en) 1996-09-23
EP0733372A3 (de) 1998-05-20
JPH08268915A (ja) 1996-10-15
KR100194987B1 (ko) 1999-06-15
NZ286207A (en) 1997-04-24
US5726164A (en) 1998-03-10
KR960036463A (ko) 1996-10-28
KR100191219B1 (ko) 1999-06-15
KR960033470A (ko) 1996-10-22
KR960033471A (ko) 1996-10-22
HUP9600701A2 (en) 1997-02-28
MX9601032A (es) 1998-11-29
EP0733358A2 (de) 1996-09-25
HUP9600701A3 (en) 2000-06-28
KR960035462A (ko) 1996-10-24
AU4809596A (en) 1996-10-03
IL117551A0 (en) 1996-07-23
NZ286206A (en) 1997-05-26
HU9600701D0 (en) 1996-05-28
NO961136L (no) 1996-09-23
CA2172111A1 (en) 1996-09-22
NO961136D0 (no) 1996-03-20
NO961137D0 (no) 1996-03-20
AU4809496A (en) 1996-10-03
EP0733358A3 (de) 1998-05-20
CA2172110A1 (en) 1996-09-22
KR960035306A (ko) 1996-10-24
ZA962249B (en) 1996-09-23
KR100191221B1 (ko) 1999-06-15
KR960034092A (ko) 1996-10-22

Similar Documents

Publication Publication Date Title
MX9601032A (es) Vehiculos farmaceuticos para nanosuspensiones.
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
AR015157A1 (es) DERIVADOS DEL ÁCIDO 5-ALQUIL-2-ARILAMINOFENILÁCETICO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE, SU USO EN LA MANUFACTURA DE UN MEDICAMENTO Y MÉTODO DE PREPARACIoN DEL MISMO
MX9709094A (es) Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina.
IT1270594B (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
HUP9803044A2 (hu) Ibuprofentartalmú készítmény
MY118371A (en) Tetrahydrolipstatin containing compositions
ES2007100A6 (es) Procedimiento para la obtencion de un sistema terapeutico oral a base de carbamazepina.
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
IS1907B (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
ATE108657T1 (de) Galanthemin enthaltende pharmazeutische formulierung zur behandlung des alkoholismus.
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
CA2215327A1 (en) Formulations for lipophilic compounds
KR970025615A (ko) 암 전이 억제제
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
IL118162A0 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
DE69928806D1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
GEP20043377B (en) Pharmaceutical Complex